Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Blood (2023) 142 (Supplement 1): 3164.

https://doi.org/10.1182/blood-2023-178790

Published: 2023

Journal Articles

Enhanced Cardiovascular Risk Assessment Incorporating Natural Language Processing and Qrisk-3 Score Determination in Patients with Essential Thrombocythaemia

Patrick Harrington, Andrea Duminuco, Joshua Au Yeung, Sukhraj Singh Virdee, Raj Vaghela, Susan Asirvatham, Rosemarie Bone, Claire Woodley, Kyaw Htin Thaw, Llywelyn Cadman-Davies, Jennifer O'Sullivan, Priya Sriskandarajah, Natalia Curto-Garcia, Shahram Kordasti, Hugues de Lavallade, Deepti H. Radia, James Teo, Claire N Harrison

Blood (2023) 142 (Supplement 1): 4561.

https://doi.org/10.1182/blood-2023-180536

Published: 2023

Journal Articles

Molecular Response of ≤10% BCR::ABL1 IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

Blood (2022) 140 (Supplement 1): 6760–6762.

https://doi.org/10.1182/blood-2022-157956

Published: 2022

Journal Articles

Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Blood (2022) 140 (Supplement 1): 1495–1497.

https://doi.org/10.1182/blood-2022-157822

Published: 2022

Journal Articles

Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy

Blood (2022) 140 (Supplement 1): 205–207.

https://doi.org/10.1182/blood-2022-166452

Published: 2022

Journal Articles

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

Blood (2021) 138 (21): 2042–2050.

https://doi.org/10.1182/blood.2021012082

Published: 2021

Includes: Supplemental data

Journal Articles

Low Frequency of T Cell and Antibody Responses to Vaccination Against Sars-Cov-2 in Patients Post Allogeneic Stem Cell Transplantation in Comparison with Chronic Myeloid Malignancy Patients

Blood (2021) 138 (Supplement 1): 3920.

https://doi.org/10.1182/blood-2021-152287

Published: 2021

Journal Articles

Post Hoc Analysis of Responses to Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) By Baseline BCR-ABL1 Level and Baseline Mutation Status in the Optic Trial

Michael W. Deininger, Jane F Apperley, Christopher Kevin Arthur, Charles Chuah, Andreas Hochhaus, Hugues De Lavallade, Jeffrey H. Lipton, Elza Lomaia, James K McCloskey, Lori J. Maness, Michael J. Mauro, Beatriz Moiraghi, Carolina Pavlovsky, Gianantonio Rosti, Philippe Rousselot, Soledad S. Undurraga, Vickie Lu, Alexander Vorog, Jorge E. Cortes

Blood (2021) 138 (Supplement 1): 307.

https://doi.org/10.1182/blood-2021-145995

Published: 2021

Journal Articles

Immune Checkpoint Analysis of T Effectors and Regulatory T Cells in Patients with CML Reveals Increased Expression at Diagnosis and with Refractory Disease

Patrick Harrington, Richard Dillon, Deepti H. Radia, Donal P. McLornan, Claire Woodley, Susan Asirvatham, Kavita Raj, Natalia Curto-Garcia, Shahram Kordasti, Claire N. Harrison, Hugues de Lavallade

Blood (2021) 138 (Supplement 1): 2545.

https://doi.org/10.1182/blood-2021-150533

Published: 2021

Journal Articles

Ponatinib in Combination with FLAG-IDA Chemotherapy for Blast-Phase Chronic Myeloid Leukemia: Final Results of the Seamless Phase I/II Dose-Finding UK Trials Acceleration Programme (TAP) Matchpoint Trial

Mhairi Copland, Daniel Slade, Graham McIlroy, Gillian Horne, Jennifer Byrne, Kate Rothwell, Kristian Brock, Hugues De Lavallade, Charles Craddock, Richard Clark, Matthew Smith, Rachel Fletcher, Rebecca Bishop, Dragana Milojkovic, Christina Yap

Blood (2021) 138 (Supplement 1): 312.

https://doi.org/10.1182/blood-2021-147972

Published: 2021

Journal Articles

An Update of Safety and Efficacy Results from Phase 1 Dose-Escalation and Expansion Study of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI), in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing Prior TKI Therapies

Blood (2021) 138 (Supplement 1): 309.

https://doi.org/10.1182/blood-2021-152548

Published: 2021

Journal Articles

Inhibition of Immune Cell Subsets Is Differentially Affected By Dasatinib Dosage in Patients with Chronic Phase CML

Patrick Harrington, MRCP, FRCPath, Richard Dillon, MA, PhD MRCP, FRCPath, Deepti H. Radia, MRCPI, FRCPath, Donal P. McLornan, MRCP, PhD FRCPath, Philippe Rousselot, MDPhD, Katayoun Rezvani, MD PhD, Shahram Kordasti, MD PhD, Claire Harrison, DM, FRCP, FRCPath, Hugues de Lavallade, MD PhD

Blood (2020) 136 (Supplement 1): 51–53.

https://doi.org/10.1182/blood-2020-139501

Published: 2020

Journal Articles

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

Jorge E. Cortes, MD, Jane Apperley, FRCP, FRCPath, MB, Andreas Hochhaus, MD, Michael J. Mauro, MD, Philippe Rousselot, MDPhD, Tomasz Sacha, MDPhD, Moshe Talpaz, MD, Charles Chuah, MD, Jeffrey H. Lipton, MD PhD, Michael W. Deininger, MD PhD, Charles A. Schiffer, MD, Lori J. Maness, MD, James K. McCloskey, MD, Valentín García Gutiérrez, MD PhD, Hugues de Lavallade, MD PhD, Gabriel Etienne, MD PhD, Vickie Lu, PhD, Shouryadeep Srivastava, MBBS, PhD, Gianantonio Rosti, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-135883

Published: 2020

Journal Articles

Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-139847

Published: 2020

Journal Articles

Prospective Evaluation of ABL Kinase Domain Mutational Analysis By Next-Generation-Sequencing in Newly Diagnosed CP CML Patients Undergoing First-Line Treatment with Nilotinib Alone or Nilotinib + Pegylated Interferon-α2a in a Prospective Phase III Trial

Hugues de Lavallade, MD PhD, Sophie Jackson, BSc, Aytug Kizilors, PhD, Gabriel Etienne, MD PhD, Francoise Huguet, MD, Agnes Guerci-Bresler, MD PhD, Delphine Rea, MD, Claudine Chollet, MSc, Stephane Morisset, BioStat, Fanny Robbesyn, BSc, Francois-Xavier Mahon, MD PhD, Stephanie Dulucq, PharmD, PhD, Franck E Nicolini, MD PhD

Blood (2019) 134 (Supplement_1): 664.

https://doi.org/10.1182/blood-2019-125108

Published: 2019

Journal Articles

Mechanistic Insights into the Inhibition of T Regulatory Cells By Dasatinib May Predict Immunostimulatory Effects in CML Patients

Patrick Harrington, MRCP, FRCPath, Richard Dillon, MA, PhD MRCP, FRCPath, Philippe Rousselot, MD PhD, Deepti Radia, Yvonne Francis, Claire N Harrison, Professor, Shahram Kordasti, MD PhD, Hugues De Lavallade

Blood (2019) 134 (Supplement_1): 1635.

https://doi.org/10.1182/blood-2019-129135

Published: 2019

Journal Articles

Sequence of Second Generation Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Patients with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia - Real World Experience in the UK

Jenny Byrne, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Adam J. Mead, MD PhD, Heather Oakervee, BSc, MBBS, MD MRCP, FRCPath, Gavin Campbell, FRCP,FRCPath, Ian Amott, Andrew Goringe, Earnest Heartin, Evangelia Dimitriadou, MD, Ian Pamphlett, Siamak Arami, MD MRCP, FRCPath, Pratap Neelakantan, Rebecca Frewin, Srinivas Pillai, MBBS,MD MRCP, FRCPath, Hugues De Lavallade, Nicholas C.P. Cross, Michael Thompson

Blood (2019) 134 (Supplement_1): 3434.

https://doi.org/10.1182/blood-2019-122893

Published: 2019

Journal Articles

Attenuated Immune Responses to the Annual Influenza A Vaccine in Patients with Myeloproliferative Neoplasms

Samah Alimam, FRCPath, Jessica Ann Timms, Richard Dillon, MA, PhD MRCP, FRCPath, Tracey Mare, Deepti Radia, Hugues De Lavallade, Claire N Harrison, Professor, Shahram Kordasti, MD PhD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath

Blood (2019) 134 (Supplement_1): 1673.

https://doi.org/10.1182/blood-2019-129091

Published: 2019

Journal Articles

Interim Analysis of a Prospective Multicentre Study Using Next Generation Sequencing for Kinase Domain Mutational Analysis in CML Patients on First or Subsequent TKI Therapy

Blood (2019) 134 (Supplement_1): 2935.

https://doi.org/10.1182/blood-2019-129825

Published: 2019

Journal Articles

Differential Alemtuzumab Dosage Effects in T-Cell Deplete Allogeneic Haematopoietic Stem Cell Transplants for Myeloid Malignancies- King's College Hospital London Experience

Varun Mehra, MBBS,MRCP,FRCPath, Daniele Avenoso, MD, Ximena Cabrera Castellano, Adrian Choy, Stefani Widya, Mili Shah, FRCPath, Shafqat Inam, MD, Shreyans Gandhi, MBBS,MDDNB,MRCP,FRCPath,MPhil, Austin Kulasekararaj, MD MRCP, FRCPath, Francesco Dazzi, PhD, Ghulam J. Mufti, MBBS, FRCP, FRCPath, DM, Antonio Pagliuca, MBBS, MA, FRCP, FRCPath, Hugues De Lavallade, Victoria Potter, MBBS, BSc, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 4622.

https://doi.org/10.1182/blood-2019-131239

Published: 2019

NARROW

Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Enhanced Cardiovascular Risk Assessment Incorporating Natural Language Processing and Qrisk-3 Score Determination in Patients with Essential Thrombocythaemia

Molecular Response of ≤10% BCR::ABL1 IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

Low Frequency of T Cell and Antibody Responses to Vaccination Against Sars-Cov-2 in Patients Post Allogeneic Stem Cell Transplantation in Comparison with Chronic Myeloid Malignancy Patients

Post Hoc Analysis of Responses to Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) By Baseline BCR-ABL1 Level and Baseline Mutation Status in the Optic Trial

Immune Checkpoint Analysis of T Effectors and Regulatory T Cells in Patients with CML Reveals Increased Expression at Diagnosis and with Refractory Disease

Ponatinib in Combination with FLAG-IDA Chemotherapy for Blast-Phase Chronic Myeloid Leukemia: Final Results of the Seamless Phase I/II Dose-Finding UK Trials Acceleration Programme (TAP) Matchpoint Trial

Inhibition of Immune Cell Subsets Is Differentially Affected By Dasatinib Dosage in Patients with Chronic Phase CML

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

Prospective Evaluation of ABL Kinase Domain Mutational Analysis By Next-Generation-Sequencing in Newly Diagnosed CP CML Patients Undergoing First-Line Treatment with Nilotinib Alone or Nilotinib + Pegylated Interferon-α2a in a Prospective Phase III Trial

Mechanistic Insights into the Inhibition of T Regulatory Cells By Dasatinib May Predict Immunostimulatory Effects in CML Patients

Sequence of Second Generation Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Patients with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia - Real World Experience in the UK

Attenuated Immune Responses to the Annual Influenza A Vaccine in Patients with Myeloproliferative Neoplasms

Interim Analysis of a Prospective Multicentre Study Using Next Generation Sequencing for Kinase Domain Mutational Analysis in CML Patients on First or Subsequent TKI Therapy

Differential Alemtuzumab Dosage Effects in T-Cell Deplete Allogeneic Haematopoietic Stem Cell Transplants for Myeloid Malignancies- King's College Hospital London Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only